Account
Watchlists
Bookmarks
Pricing
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Bearish
2
Neutral
8
Bullish
4
Bearish
13
Neutral
16
Bullish
17
Bearish
11
Neutral
8
Bullish
13
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Market Cap
₹ 65 Cr
P/E
54.82
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products.
The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India.
Kabra Drugs maintains state-of-the-art facilities approved by WHO-GMP, cGMP, and Schedule 'M', enabling business with government entities and NGOS.
Despite manufacturing capabilities, the company is facing operational challenges due to lack of working capital, prompting cost reduction efforts.
Kabra Drugs is a registered supplier to the Ministry of Defence and aims to expand its reach to global markets with new product developments.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
65 Cr
Low Risk
54.8
43.8
—
2.5
32.66
10.06
Sales CAGR
1Y
—
3Y
—
5Y
—
10Y
—
Profit CAGR
1Y
-47.30%
3Y
—
5Y
—
10Y
—
ROE
TTM
4.59%
3Y
-8.64%
5Y
-10.35%
10Y
-16.61%
ROCE
TTM
5.90%
3Y
-8.63%
5Y
-10.34%
10Y
-13.01%
Turned 1 L into 2.77 L in last 1 Year
Performance
MARKET LEADER
Valuation
OVERVALUED
Growth
STABLE
Profitability
MODERATE MARGIN
Technicals
Bullish
Risk
MODERATE RISK
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
52.15 | 89 Cr | 8.51 | 1.44 | 0.00 | 15.41 | 18.92 | 6.93 | |
18.94 | 82 Cr | — | 0.00 | 0.00 | -22.95 | -11.16 | -9.61 | |
120.00 | 71 Cr | — | 1.00 | 0.00 | -0.03 | 8.67 | 2.48 | |
27.50 | 65 Cr | 54.82 | 2.50 | 0.00 | 4.59 | 5.90 | 2.18 | |
35.00 | 57 Cr | 19.89 | 2.67 | 0.00 | 13.42 | 15.83 | 5.15 | |
8.50 | 52 Cr | — | 1.16 | 0.00 | -15.00 | -13.49 | -10.99 | |
39.30 | 38 Cr | 24.34 | 1.13 | 2.04 | 3.69 | 5.32 | 2.80 |
